Testosterone Cypionate
Testosterone Replacement Therapy (TRT) — Long-Acting Injectable Androgen
Overview & Background
Testosterone Cypionate is a synthetic ester of testosterone — the primary male sex hormone — formulated as an oil-based injectable for intramuscular or subcutaneous administration. The cypionate ester (cyclopentylpropionate) is attached to the testosterone molecule at the 17-beta hydroxyl position, creating a depot formulation that is slowly hydrolyzed at the injection site, releasing free testosterone into the bloodstream over approximately 7–10 days. This pharmacokinetic profile enables once-weekly or twice-weekly dosing schedules, making it one of the most practical and widely prescribed testosterone formulations in the United States.
Testosterone itself is an endogenous steroid hormone produced primarily by the Leydig cells of the testes in males (and in smaller amounts by the ovaries and adrenal glands in females). It is essential for the development and maintenance of male secondary sexual characteristics, reproductive function, muscle mass and strength, bone density, erythropoiesis (red blood cell production), mood, cognitive function, libido, and overall vitality. Hypogonadism — the clinical state of insufficient testosterone production — affects an estimated 2–6 million men in the United States and is associated with a broad constellation of symptoms including fatigue, decreased libido, erectile dysfunction, reduced muscle mass, increased body fat, depression, and cognitive impairment.
Testosterone replacement therapy (TRT) with testosterone cypionate is FDA-approved for the treatment of hypogonadism in adult males when confirmed by clinical symptoms and laboratory testing showing low serum testosterone. Its use has expanded significantly in recent decades, both within traditional endocrinological practice and within the growing field of men's health and hormone optimization medicine, where it is used to restore testosterone levels to the mid-to-upper end of the physiological reference range in symptomatic individuals.
Clinical Research & Evidence
The clinical evidence for testosterone replacement therapy in hypogonadal men is substantial and spans decades of research. The landmark Testosterone Trials (TTrials), a coordinated set of seven trials enrolling 788 men aged 65 and older with low testosterone and symptoms of hypogonadism, demonstrated that TRT significantly improved sexual function, physical function (particularly walking distance), bone mineral density, and anemia. The sexual function improvements were the most consistent and clinically meaningful finding across trials.
More recently, the TRAVERSE trial (2023) enrolled 5,246 men with hypogonadism and pre-existing cardiovascular disease or high cardiovascular risk. This landmark study found that testosterone replacement did not increase the incidence of major adverse cardiovascular events (MACE) compared to placebo — addressing a long-standing concern that had made many clinicians hesitant to prescribe TRT in cardiovascular patients. Notably, the trial did find increased rates of atrial fibrillation, pulmonary embolism, and acute kidney injury in the testosterone group, underscoring the importance of appropriate patient selection and monitoring.
Evidence also supports TRT's role in improving body composition (increased lean mass, reduced fat mass), metabolic parameters (improved insulin sensitivity, reduced HbA1c in hypogonadal men with diabetes), and bone mineral density (particularly important in older men at risk for osteoporosis). The magnitude of these benefits varies with baseline testosterone levels, age, and duration of treatment. Men with severely low testosterone and high symptom burden typically experience the most dramatic improvements.
Reported Benefits
Energy and vitality restoration is among the most consistently reported benefits of TRT in hypogonadal men. The profound fatigue and motivational deficits associated with low testosterone are frequently among the first symptoms to improve after TRT initiation, often within the first 3–6 weeks of treatment. Many patients describe a qualitative shift in how they feel — a return to a baseline energy level they had not experienced in years — that has significant impacts on work performance, relationship quality, and overall wellbeing.
Body composition improvements are well-documented and compound over time. TRT consistently increases lean muscle mass and reduces fat mass, particularly visceral (abdominal) fat, even without changes in exercise habits — though the effects are substantially amplified by resistance training. For men with hypogonadism who struggle to maintain or build muscle despite adequate training and nutrition, TRT often represents the missing physiological foundation that makes these efforts productive. The magnitude of body composition change is greater in men with lower baseline testosterone.
Sexual health benefits — improved libido, sexual desire, erectile function, and overall sexual satisfaction — are among the most impactful for patients' quality of life. The relationship between testosterone and sexual function is dose-dependent up to a threshold, above which additional testosterone does not further improve sexual outcomes. Mood improvements, including reduced depression, irritability, and anxiety, are also commonly reported and may be partially mediated through testosterone's direct effects on the central nervous system and partially through secondary improvements in sleep, energy, and body composition.
Dosing Protocols
Standard TRT dosing with testosterone cypionate ranges from 100–200mg per week, with most physicians initiating at 100mg weekly and adjusting based on total testosterone, free testosterone, and symptom response at 6–8 week follow-up. The goal is typically to achieve mid-to-upper normal range total testosterone (500–900 ng/dL) and free testosterone in the upper quartile of the normal range. Higher doses (above 200mg/week) move into supraphysiological territory and are generally not appropriate for standard TRT, though they are used in the context of performance enhancement.
Injection frequency significantly affects hormone stability and side effect profiles. Once-weekly injection of the full dose is convenient but produces peaks and troughs — higher levels in the first 2–3 days post-injection and lower levels by day 6–7. Splitting the dose into twice-weekly injections (e.g., 50mg Monday and Thursday) produces more stable serum levels, often reduces estradiol-related side effects (as the body has less substrate for aromatization at any given time), and is the preferred protocol for most men optimizing for symptom consistency and minimizing side effects.
Some clinicians use even more frequent administration — every other day (EOD) or daily micro-dosing via subcutaneous injection — to approximate the natural testosterone secretion pattern and minimize fluctuations. Daily SubQ injection of 10–15mg produces extremely stable serum levels and is particularly favored by men who are sensitive to estradiol fluctuations. This approach requires greater adherence and more frequent injections but offers superior hormonal stability compared to less frequent IM protocols.
Preparation & Administration Notes
Testosterone cypionate comes as a pre-dissolved oil-based solution (typically 200mg/mL in cottonseed or grapeseed oil) — no reconstitution is required. The solution should be drawn from the vial using a larger-gauge needle (18–21G) for efficient drawing, then the needle is swapped for the injection needle before administration. Warming the vial slightly (brief warm water bath or between palms for 30 seconds) reduces the viscosity of the oil, making it easier to draw and inject.
For intramuscular injection, common sites include the gluteus medius (ventrogluteal), the vastus lateralis (outer thigh), and the deltoid. The ventrogluteal site is generally preferred by experienced injectors due to its distance from major nerves and blood vessels. For subcutaneous injection, the abdomen and outer thigh are most commonly used, with 25–27G needles of 5/8 inch length appropriate for most individuals. SubQ injections of testosterone cypionate have been shown to produce comparable testosterone levels to IM with good tolerability.
Proper site rotation is essential for all injection routes to prevent scar tissue accumulation, lipohypertrophy, and local irritation. Maintaining an injection log — tracking site, date, dose, and any reactions — is strongly recommended and is one of the core features Dosi provides for testosterone tracking. Consistency of injection technique directly impacts the consistency of testosterone levels and, consequently, symptom stability.
Half-Life & Pharmacokinetics
Testosterone cypionate has a half-life of approximately 8 days, which is slightly longer than testosterone enanthate (~7 days) and significantly longer than testosterone propionate (~2 days) or testosterone suspension (hours). After intramuscular injection, the ester slowly diffuses from the oil depot into surrounding tissue, where esterases cleave the cypionate ester to release free testosterone into the bloodstream. Peak serum testosterone typically occurs 24–72 hours after IM injection.
Free testosterone circulates briefly before binding to sex hormone-binding globulin (SHBG) and albumin, with only 2–3% remaining as truly free, biologically active hormone. Testosterone is metabolized by 5-alpha reductase to dihydrotestosterone (DHT) — a more potent androgen responsible for prostate effects and male pattern hair loss — and by aromatase (primarily in adipose tissue) to estradiol (E2). Understanding these conversion pathways is essential for managing TRT side effects, as elevated estradiol from excessive aromatization is one of the most common TRT management challenges.
The 8-day half-life means it takes approximately 5–6 weeks of consistent weekly dosing to reach true steady-state serum testosterone concentrations. This is why TRT labs are typically drawn at 6–8 weeks after dose initiation or change, not earlier. Drawing labs too early (before steady state) provides misleading information and can lead to premature dose adjustments. Similarly, if TRT is discontinued, testosterone levels will not fully clear for approximately 5–6 weeks.
Side Effects & Contraindications
Erythrocytosis (elevated hematocrit and red blood cell count) is the most clinically significant side effect of TRT and requires monitoring. Testosterone stimulates erythropoiesis, and hematocrit can rise above safe thresholds (typically >54% is considered concerning) in a subset of men, increasing blood viscosity and theoretically raising risk for clotting events. Management options include dose reduction, increased injection frequency (more stable levels reduce erythrocytosis), therapeutic phlebotomy (blood donation), and in refractory cases, discontinuation. Men who donate blood regularly often maintain safer hematocrit levels on TRT.
Estradiol elevation from testosterone aromatization can cause gynecomastia (breast tissue development), water retention, mood instability, and sexual dysfunction in some men. Management involves optimizing injection frequency (twice-weekly produces lower estradiol peaks), reducing dose if supra-physiological, and in some cases using low-dose aromatase inhibitors (anastrozole, exemestane). However, routine use of aromatase inhibitors on TRT is increasingly discouraged — estradiol is important for bone health, cardiovascular function, libido, and joint health, and over-suppression creates its own problems. Target estradiol on TRT is typically 20–40 pg/mL.
Absolute contraindications include: active prostate cancer or breast cancer (testosterone is a growth signal for hormone-sensitive cancers), untreated severe sleep apnea (testosterone can worsen OSA), desire for future fertility (exogenous testosterone suppresses LH/FSH and stops spermatogenesis — men desiring fertility should consider hCG-based protocols instead), and hematocrit above 54% at baseline. Relative contraindications include severe benign prostatic hyperplasia (BPH), active cardiovascular disease requiring careful management, and severe liver disease.
Stacking Protocols
For men on TRT who want to preserve testicular function and fertility, human chorionic gonadotropin (hCG) is the most common co-administration. hCG mimics LH, stimulating the Leydig cells to continue producing endogenous testosterone and maintaining testicular size and spermatogenesis. Typical hCG dosing alongside TRT is 500–1000 IU 2–3 times per week. Some clinicians use HMG (human menopausal gonadotropin) for men specifically trying to maintain fertility on TRT.
Peptide stacking with testosterone is common in the men's health and performance medicine space. Growth hormone secretagogues (CJC-1295/ipamorelin, MK-677) are frequently combined with TRT to amplify body composition benefits — testosterone optimizes the androgen environment while GH axis support enhances fat loss and muscle protein synthesis. This combination addresses both the androgen and growth hormone axes simultaneously, which decline in parallel with aging. BPC-157 is sometimes added for joint health support, as TRT-driven training intensity can increase musculoskeletal injury risk.
For men using testosterone cypionate in performance enhancement contexts (above physiological TRT doses), the pharmacological complexity increases substantially. These protocols are outside the scope of standard TRT management and require sophisticated monitoring of multiple hormonal axes, lipid parameters, cardiovascular markers, and organ function. Any supraphysiological testosterone use carries meaningfully elevated risks compared to physiological replacement and should be approached with clear-eyed awareness of those risks rather than dismissal.
Storage & Stability
Testosterone cypionate in oil solution is more stable than peptide formulations and does not require refrigeration under normal conditions. It should be stored at controlled room temperature (20–25°C / 68–77°F), protected from light (keep in the original box or a dark storage location), and away from excessive heat. The multi-dose vials are designed to be used over time — each properly sterile draw should not compromise the remaining solution if aseptic technique is maintained.
Refrigeration is not required but will not harm the product — some individuals prefer to refrigerate to maximize shelf stability and extend the expiration date. If refrigerated, allow the vial to come to room temperature before drawing the dose, as cold oil is more viscous and difficult to draw cleanly. Never freeze testosterone cypionate — freezing can cause the solution to crystallize or the oil-water emulsion to separate, potentially affecting dose accuracy.
Inspect each vial before use for cloudiness, particulates, or discoloration — though testosterone cypionate in clear oil is normally slightly yellow in color, which is normal. Contamination with bacteria or fungi can occur if aseptic technique is not maintained during drawing. Discard any vial that appears contaminated or that has been stored past its expiration date. Multi-dose vials from compounding pharmacies typically have shorter beyond-use dates (BUDs) than commercially manufactured products.
Legal Status & Availability
Testosterone cypionate is an FDA-approved Schedule III controlled substance in the United States. It is legally available by prescription only and is manufactured commercially by multiple pharmaceutical companies (Depo-Testosterone by Pfizer is the branded version; multiple generics exist). Prescriptions are issued by licensed physicians — typically urologists, endocrinologists, internal medicine physicians, or men's health specialists — after clinical evaluation and laboratory confirmation of hypogonadism.
Compounding pharmacies can also prepare testosterone cypionate at custom concentrations or in alternative carrier oils (grapeseed, MCT) under physician prescription, which is particularly useful for men who experience injection site reactions from the standard cottonseed oil formulation. The compounded product is not subject to the same FDA manufacturing oversight as commercially approved products, though reputable PCAB-accredited compounding pharmacies maintain high quality standards.
Possession of testosterone without a valid prescription is a federal felony in the United States and carries criminal penalties. The drug is also prohibited in competitive sports by WADA and virtually all sports governing bodies. International travelers carrying testosterone should carry the original prescription bottle, a physician letter, and be aware of the legal status in destination countries — controlled substance schedules vary significantly internationally, and some countries have strict importation restrictions regardless of prescription status.
Bloodwork & Monitoring
Comprehensive pre-TRT baseline labs are essential and medically required before initiating therapy. The minimum panel includes: total testosterone (two morning measurements for confirmation), free testosterone, LH and FSH (to distinguish primary from secondary hypogonadism), complete blood count with hematocrit, comprehensive metabolic panel, PSA (prostate-specific antigen), lipid panel, estradiol, and SHBG. Additional tests may include thyroid function, prolactin (to rule out prolactinoma), and sleep study referral if OSA is suspected.
On-therapy monitoring should occur at 6–8 weeks after initiation (once steady state is achieved), then every 3–6 months for the first year, and annually thereafter once stable. Key parameters to track: total testosterone (target 500–900 ng/dL for most TRT protocols, timed consistently relative to injection for meaningful comparison), free testosterone, estradiol (target 20–40 pg/mL), hematocrit (must remain below 54%), PSA (prostate safety monitoring — a rise of >1.4 ng/mL from baseline or above 4.0 ng/mL warrants urological evaluation), and lipids.
Blood pressure monitoring is important, as TRT can raise blood pressure in some men, particularly those with pre-existing hypertension or fluid retention tendency. Digital home blood pressure monitoring is a low-cost, high-value addition to TRT management. Sleep quality monitoring (via consumer wearables or formal sleep studies) is relevant given TRT's potential to worsen sleep apnea. The goal of comprehensive monitoring is not bureaucratic box-checking — it is to catch the minority of men who experience adverse effects early, before they become clinically significant problems, while allowing the majority to benefit safely from therapy.
Track Your TRT with Dosi
Log injections, track labs, monitor hematocrit trends, and get AI-powered TRT guidance. Free to start.
Start Tracking Free →Educational use only. This content is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before using any compound.